Morphology, Fundus Autofluorescence, and Retinal Sensitivity of Photocoagulated Lesions in Proliferative Diabetic Retinopathy-Reference-Cited by-同舟云学术

Morphology, Fundus Autofluorescence, and Retinal Sensitivity of Photocoagulated Lesions in Proliferative Diabetic Retinopathy

Published:2024-07-01 Issue:7 Volume:13 Page:1
ISSN:2164-2591
Container-title:Translational Vision Science & Technology
language:en
Short-container-title:Trans. Vis. Sci. Tech.

Author:

Nishida Kentaro¹,Kawasaki Ryo²,Fukushima Yoko¹³,Takahashi Shizuka⁴,Fujikado Takashi¹,Nishida Kohji¹³

Affiliation:

1. Department of Ophthalmology, Osaka University Graduate School of Medicine, Suita, Japan

2. Department of Public Health, Osaka University Graduate School of Medicine, Suita, Japan

3. Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, 2-2 Yamadaoka, Suita, Osaka, Japan

4. Department of Ophthalmology, Higashiosaka City Medical Center, 3-4-5 Nishi-iwata, Higashi-Osaka, Osaka, Japan

Publisher

Association for Research in Vision and Ophthalmology (ARVO)

Reference20 articles.

1. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis;Teo;Ophthalmology,2021

2. The prevalence of diabetic retinopathy among adults in the United States;Kempen;Arch Ophthalmol,2004

3. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial;Writing Committee for the Diabetic Retinopathy Clinical Research Network;JAMA,2015

4. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (Clarity): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial;Sivaprasad;Lancet,2017

5. Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: results from the PANORAMA randomized clinical trial;Brown;JAMA Ophthalmol,2021